For US Healthcare Professionals
Adverse reactions reported in ≥2% of patients treated with ORZEYFUL and greater than placebo in two phase 3 NT1 studies1
Adverse Reaction | Placebo
| ORZEYFUL 1 mg
| ORZEYFUL 2 mg*
|
Insomnia† | 1 | 55 | 60 |
Urinary frequency | 5 | 53 | 58 |
Urinary frequency | 1 | 15 | 16 |
Salivary hypersecretion | 0 | 8 | 7 |
Influenza | 1 | 5 | 3 |
Abdominal pain | 0 | 3 | 1 |
Oropharyngeal pain | 0 | 3 | 1 |
Paresthesia | 0 | 2 | 2 |
Rash | 0 | 0 | 3 |
Sinusitis | 1 | 5 | 2 |
Adverse Reaction
Insomnia† | |
Placebo
| 1 |
| ORZEYFUL 1 mg twice daily (n=60) % | 55 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 60 |
Urinary frequency (pollakiuria) | |
Placebo
| 5 |
| ORZEYFUL 1 mg twice daily (n=60) % | 53 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 58 |
Urinary urgency (micturition urgency) | |
Placebo
| 1 |
| ORZEYFUL 1 mg twice daily (n=60) % | 15 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 16 |
Salivary hypersecretion | |
Placebo
| 0 |
| ORZEYFUL 1 mg twice daily (n=60) % | 8 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 7 |
Influenza | |
Placebo
| 1 |
| ORZEYFUL 1 mg twice daily (n=60) % | 5 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 3 |
Abdominal pain | |
Placebo
| 0 |
| ORZEYFUL 1 mg twice daily (n=60) % | 3 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 1 |
Oropharyngeal pain | |
Placebo
| 0 |
| ORZEYFUL 1 mg twice daily (n=60) % | 3 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 1 |
Paresthesia | |
Placebo
| 0 |
| ORZEYFUL 1 mg twice daily (n=60) % | 2 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 2 |
Rash | |
Placebo
| 0 |
| ORZEYFUL 1 mg twice daily (n=60) % | 0 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 3 |
Sinusitis | |
Placebo
| 1 |
| ORZEYFUL 1 mg twice daily (n=60) % | 5 |
| ORZEYFUL 2 mg* twice daily (n=136) % | 2 |
*The 2 ORZEYFUL doses were taken at least 3 hours apart with the second dose taken no later than 1 PM.1
†Includes insomnia, middle insomnia, and initial insomnia.1
Insomnia events1
- Insomnia occurred in 58% of ORZEYFUL-treated patients and severe insomnia occurred in 1.5% of ORZEYFUL-treated patients
- Approximately 90% started within the first 2 days of therapy initiation, and 4% began between days 2 and 7 of therapy initiation
- Approximately 63% resolved within 1 week of onset, and approximately 17% were ongoing at study completion
- None led to study discontinuation or were classified as serious adverse reactions
Urinary events1
- Urinary adverse reactions occurred in 63% of ORZEYFUL-treated patients and severe urinary adverse reactions occurred in 1% of ORZEYFUL-treated patients
- Two ORZEYFUL-treated patients discontinued treatment, one due to frequent urination and the other due to urinary incontinence
Safety profile evaluated in
196 patients
across phase 3 trials1
<3% of patients
treated with ORZEYFUL discontinued due to adverse reactions1
Connect with us
Get resources and information about ORZEYFUL or request to speak with a Takeda representative
Recommended for you
NT1=narcolepsy type 1.
Reference: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals.